The lalulife Company Limited
Update：2024/12/24
Industries
Main Industry
Community and Lifestyle
Main Product/Service
Over the past decade, Bora has built a strong foundation in developing hard-to-formulate and controlled release generic pharmaceutical products for the US market, offering patients affordable, high quality essential medicines.
To further address the unmet medical needs, we have shifted our focus of research and development from generic products to innovative medicines. Our development strategy now focuses on central nervous system diseases (CNS), with further concentration on epilepsy/seizure, ADHD, and depression, especially for pediatric patients.
We continue to strengthen our core technologies in nano-formulation, controlled-release, and prodrug design platform to drive innovation through re-formulation, repurposing, and new combinations—enabling us to develop potential “best-in-class” treatments for diseases in our focus areas, such as rare pediatric epilepsy, and other high unmet medical needs.
Clinical Trial Standards
A.Commitment to Animal Welfare in Preclinical Animal Studies
To ensure compliance with animal welfare, Bora Pharmaceuticals selects GLP certified contract research organizations (CROs). These organizations must follow the Institutional Animal Care and Use Committee (IACUC) regulations and adhere to the 3R principles (Refine, Reduce, Replace). This approach complies with the animal welfare committee guidelines for humane experimentation. Currently, we have contracted 3 qualified CROs in Taiwan for preclinical animal studies. We commit to applying the same standards to our overseas subsidiaries in the future.
B. Standards for Clinical Trial Monitoring and Auditing
Bora collaborates with international research institutions to conduct clinical trials in countries including the United States, Canada, India, and China. All clinical trials intended for regulatory submission are conducted by independent clinical trial quality assurance organizations to ensure rigorous quality oversight. Through
contracted CROs, risk-based monitoring and audit plans are developed and implemented to ensure the quality and integrity of investigational drug studies. Participant rights and welfare are prioritized, with strict adherence to trial protocols, Good Clinical Practice (GCP) guidelines, and applicable regulatory requirements to ensure full compliance in trial execution, data collection, documentation, and reporting.
To further address the unmet medical needs, we have shifted our focus of research and development from generic products to innovative medicines. Our development strategy now focuses on central nervous system diseases (CNS), with further concentration on epilepsy/seizure, ADHD, and depression, especially for pediatric patients.
We continue to strengthen our core technologies in nano-formulation, controlled-release, and prodrug design platform to drive innovation through re-formulation, repurposing, and new combinations—enabling us to develop potential “best-in-class” treatments for diseases in our focus areas, such as rare pediatric epilepsy, and other high unmet medical needs.
Clinical Trial Standards
A.Commitment to Animal Welfare in Preclinical Animal Studies
To ensure compliance with animal welfare, Bora Pharmaceuticals selects GLP certified contract research organizations (CROs). These organizations must follow the Institutional Animal Care and Use Committee (IACUC) regulations and adhere to the 3R principles (Refine, Reduce, Replace). This approach complies with the animal welfare committee guidelines for humane experimentation. Currently, we have contracted 3 qualified CROs in Taiwan for preclinical animal studies. We commit to applying the same standards to our overseas subsidiaries in the future.
B. Standards for Clinical Trial Monitoring and Auditing
Bora collaborates with international research institutions to conduct clinical trials in countries including the United States, Canada, India, and China. All clinical trials intended for regulatory submission are conducted by independent clinical trial quality assurance organizations to ensure rigorous quality oversight. Through
contracted CROs, risk-based monitoring and audit plans are developed and implemented to ensure the quality and integrity of investigational drug studies. Participant rights and welfare are prioritized, with strict adherence to trial protocols, Good Clinical Practice (GCP) guidelines, and applicable regulatory requirements to ensure full compliance in trial execution, data collection, documentation, and reporting.
Founded Year
2021
Unified Business No.
91099902
Status
Active
Number of Employees
7
Total Paid-in
Capital
300,000 (NT$)
Location of Company
Taiwan
, Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Founded in 2007, Bora Pharmaceuticals continues to gain industry trust, significantly expanding market penetration through premium CDMO services. Our distinctive dual-engine strategy integrates scalable, high-quality CDMO growth with innovative drug development focused on specialty pharma and rare diseases. Strategic investments in manufacturing capabilities, operational excellence, and specialized talents are the pillars that sustain our valued partnerships in the industry. At Bora, we take pride in accelerating access to transformative treatments by enabling genuine, decisive progress.
